{
    "clinical_study": {
        "@rank": "33456", 
        "arm_group": [
            {
                "arm_group_label": "A", 
                "arm_group_type": "Experimental", 
                "description": "5th dose of vaccine"
            }, 
            {
                "arm_group_label": "B", 
                "arm_group_type": "No Intervention", 
                "description": "Blood draw only"
            }, 
            {
                "arm_group_label": "C", 
                "arm_group_type": "Experimental", 
                "description": "4th dose of vaccine (3 \u00bd, 5 + booster at 11 months of age)"
            }, 
            {
                "arm_group_label": "D", 
                "arm_group_type": "No Intervention", 
                "description": "Blood draw only"
            }, 
            {
                "arm_group_label": "E", 
                "arm_group_type": "Experimental", 
                "description": "4th dose of vaccine (6, 8 + booster at 11 months of age)"
            }, 
            {
                "arm_group_label": "F", 
                "arm_group_type": "No Intervention", 
                "description": "Blood draw only"
            }, 
            {
                "arm_group_label": "G", 
                "arm_group_type": "Experimental", 
                "description": "3rd dose of vaccine (0,2-month schedule, Subjects 2 to 5 years of age)"
            }, 
            {
                "arm_group_label": "H", 
                "arm_group_type": "No Intervention", 
                "description": "Blood draw only"
            }, 
            {
                "arm_group_label": "I", 
                "arm_group_type": "Experimental", 
                "description": "3rd dose of vaccine (0,2-month schedule, Subjects 6 to 10 years of age)"
            }, 
            {
                "arm_group_label": "J", 
                "arm_group_type": "No Intervention", 
                "description": "Blood draw only"
            }, 
            {
                "arm_group_label": "K", 
                "arm_group_type": "Experimental", 
                "description": "Na\u00efve subjects (35-47 months of age)"
            }, 
            {
                "arm_group_label": "L", 
                "arm_group_type": "Experimental", 
                "description": "Na\u00efve subjects (4 to 7 years old)"
            }, 
            {
                "arm_group_label": "M", 
                "arm_group_type": "Experimental", 
                "description": "Na\u00efve subjects (8 to 12 years old)"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this extension study is to explore the antibody persistence 24 to 36 months after\n      the last dose of vaccine, in infants that received a two or three dose primary series plus a\n      booster dose at 11 months of age, of the Novartis meningococcal B vaccine (rMenB + OMV NZ)\n      in groups I to III of the parent V72_28 study.\n\n      This study will also explore the antibody persistence 24 to 36 months after two catch-up\n      doses of the Novartis meningococcal B vaccine (rMenB + OMV NZ) administered in children (2\n      to 10 years old) in group IV of the parent V72_28 study."
        }, 
        "brief_title": "Antibody Persistence, and Safety and Tolerability of a Booster Dose of the Meningococcal B Vaccine After the Completion of the Vaccination Course in Study V72_28", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Meningoccocal Disease,", 
            "Meningococcal Meningitis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Meningitis", 
                "Meningitis, Meningococcal"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        For na\u00efve subjects newly enrolled:\n\n          1. Healthy infants and children according to the following age groups:\n\n               1. Healthy subjects from 35 to 47 months of age, (only applicable to group K) (The\n                  age window is defined as the first day the subject turns 35 months of age up to\n                  the day before the subject turns 48 months of age),\n\n               2. Healthy subjects 4 to 7 years of age (only applicable to group L) (The age\n                  window is defined as the first day the subject turns 4 years of age up to the\n                  day before the subject turns 8 years of age).\n\n               3. Healthy subjects 8 to 12 years of age (only applicable to group M) (The age\n                  window is defined as the first day the subject turns 8 years of age up to the\n                  day before the subject turns 13 years of age).\n\n          2. for whom a parent/legal guardian has given written informed consent after the nature\n             of the study has been explained;\n\n          3. for whom a parent/legal guardian confirmed availability for the visit scheduled in\n             the study;\n\n          4. in good health as determined by medical history, physical examination, clinical\n             judgment of the investigator.\n\n        For Subjects who participated in the V72_28 study (Follow-on Subjects):\n\n          1. for whom a parent/legal guardian has given written informed consent after the nature\n             of the study has been explained;\n\n          2. for whom a parent/legal guardian confirmed availability for the visit scheduled in\n             the study;\n\n          3. in good health as determined by medical history, physical examination, clinical\n             judgment of the investigator\n\n          4. who have completed the vaccination course in the V72_28 study and have received their\n             last vaccination 24 to 36 months before enrollment in V72_28E1\n\n        Exclusion Criteria:\n\n        For na\u00efve subjects newly enrolled:\n\n          1. History of any serogroup B meningococcal vaccine administration;\n\n          2. Previous known or suspected disease caused by N. meningitidis;\n\n          3. Household contact with and/or intimate exposure to an individual with laboratory\n             confirmed N. meningitidis infection or colonization;\n\n          4. History of severe allergic reaction after previous vaccinations or hypersensitivity\n             to any component of the vaccine;\n\n          5. Pregnancy or nursing (breastfeeding) mothers;\n\n          6. Females of childbearing age who have not used or do not plan to use acceptable birth\n             control measures, for the duration of the study. Oral, injected or implanted hormonal\n             contraceptive, barrier methods (condom or diaphragm with spermicide), intrauterine\n             device, surgical sterilization, transdermal delivery, congenital sterility or sexual\n             abstinence are considered acceptable forms of birth control. If sexually active the\n             subject must have been using one of the accepted birth control methods at least two\n             months prior to study entry;\n\n          7. Known or suspected autoimmune disease or impairment/alteration of the immune system\n             resulting from (for example):\n\n               -  Receipt of any chronic immunosuppressive therapy\n\n               -  Receipt of any chronic immunostimulants\n\n               -  Immune deficiency disorder, or known HIV infection\n\n          8. History of seizure, any progressive neurological disease or Guillain Barr\u00e9 Syndrome\n             (exception: one self-limited febrile seizure is acceptable).\n\n          9. Known bleeding diathesis or any condition that may be associated with a prolonged\n             bleeding time.\n\n         10. Subject's parent(s) or legal guardian(s) are not able to comprehend and to follow all\n             required study procedures for the whole period of the study.\n\n         11. Intent to participate in another clinical study during this study.\n\n         12. Family members and household members of study staff;\n\n         13. History or any illness/condition which, in the opinion of the investigator, might\n             interfere with the evaluation of the study objectives or pose additional risk to the\n             subjects due to participation in the study.\n\n         14. Any significant chronic infection.\n\n         15. Any serious chronic or progressive disease according to judgment of the investigator\n             (e.g. neoplasm, insulin dependent diabetes, cardiac, renal or hepatic disease).\n\n        For Subjects who participated in the V72_28 study (Follow-on Subjects):\n\n        Exclusion criteria are the same as for na\u00efve subjects, with the exception of criterion 1."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "12 Years", 
            "minimum_age": "35 Months"
        }, 
        "enrollment": {
            "#text": "1350", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01894919", 
            "org_study_id": "V72_28E1", 
            "secondary_id": "2012-000657-30"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "A", 
                    "C", 
                    "E", 
                    "G", 
                    "I"
                ], 
                "intervention_name": "rMenB + OMV vaccine (1 dose at study month zero)", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "K", 
                    "L", 
                    "M"
                ], 
                "intervention_name": "rMenB + OMV vaccine (2 doses 1 month apart)", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Antibodies"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Meningococcal B disease,", 
            "Antibody persistence"
        ], 
        "lastchanged_date": "April 2, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Debrecen", 
                        "country": "Hungary", 
                        "state": "Bajcsi ut 32", 
                        "zip": "4025"
                    }, 
                    "name": "Site 34, General Pediatric Practice Somorjai"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Szeged", 
                        "country": "Hungary", 
                        "state": "Csongradi sgt 63", 
                        "zip": "6723"
                    }, 
                    "name": "Site 35, Praxis Dr Eva Kovacs"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Szeged", 
                        "country": "Hungary", 
                        "state": "Debreceni utca 10-14", 
                        "zip": "6723"
                    }, 
                    "name": "Site 36, General Practice Dr Edit Oszlacs"
                }, 
                "status": "Completed"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bordany", 
                        "country": "Hungary", 
                        "state": "Honved utca 2", 
                        "zip": "6795"
                    }, 
                    "name": "Site 37, Praxis Dr Julianna Kovacs"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miskolc", 
                        "country": "Hungary", 
                        "state": "Kando Kalman utca 1", 
                        "zip": "3534"
                    }, 
                    "name": "Site 31, General Practice Dr Olga Fekete"
                }, 
                "status": "Completed"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Budapest", 
                        "country": "Hungary", 
                        "state": "Poth Iren u 80", 
                        "zip": "1188"
                    }, 
                    "name": "Site 40, General Pediatric Practice Hacsek"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miskolc", 
                        "country": "Hungary", 
                        "state": "Selyemret u. 1.", 
                        "zip": "3527"
                    }, 
                    "name": "Site 30, General Practice Dr Simko"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nyiregyhaza", 
                        "country": "Hungary", 
                        "state": "Szent Istvan u 10", 
                        "zip": "4400"
                    }, 
                    "name": "Site 33, General Pediatric Practice Ujhelyi"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Csongrad", 
                        "country": "Hungary", 
                        "state": "Szentharomsag ter 10", 
                        "zip": "6640"
                    }, 
                    "name": "Site 42, Praxis Dr Eszter Bari"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Almeria", 
                        "country": "Spain", 
                        "zip": "04007"
                    }, 
                    "name": "Site 15"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Almeria", 
                        "country": "Spain", 
                        "zip": "04120"
                    }, 
                    "name": "Site 16"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08195"
                    }, 
                    "name": "Site 20"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28041"
                    }, 
                    "name": "Site 17"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28935"
                    }, 
                    "name": "Site 18"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pontevedra", 
                        "country": "Spain", 
                        "zip": "36002"
                    }, 
                    "name": "Site 13"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santiago de Compostela", 
                        "country": "Spain", 
                        "zip": "15706"
                    }, 
                    "name": "Site 10"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain", 
                        "zip": "41014"
                    }, 
                    "name": "Site 14"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Hungary", 
                "Spain"
            ]
        }, 
        "number_of_arms": "13", 
        "official_title": "A Phase IIIb, Open Label, Multi Center Extension Study of V72_28 to Assess Antibody Persistence, and the Safety and Tolerability of a Booster Dose After the Completion of the Vaccination Course in Study V72_28", 
        "overall_contact": {
            "last_name": "Novartis Drug Information Services", 
            "phone": "18002447668"
        }, 
        "overall_official": {
            "affiliation": "Novartis Vaccines", 
            "last_name": "Novartis Vaccines and Diagnostics", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "European Union: European Medicines Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "To evaluate the antibody persistence 24 to 36 months after the completion of the vaccination course, in subjects who participated in the V72_28 study in Groups I to IV.", 
                "measure": "Percentage of subjects with hSBA titers \u2265 5 directed against strains of N. meningitidis serogroup B.", 
                "safety_issue": "No", 
                "time_frame": "At day 1"
            }, 
            {
                "description": "To evaluate the antibody persistence 24 to 36 months after the completion of the vaccination course, in subjects who participated in the V72_28 study in Groups I to IV.", 
                "measure": "Percentage of subjects with hSBA titers \u2265 8 against strains of N. meningitidis serogroup B.", 
                "safety_issue": "No", 
                "time_frame": "At day 1"
            }, 
            {
                "description": "To evaluate the antibody persistence 24 to 36 months after the completion of the vaccination course, in subjects who participated in the V72_28 study in Groups I to IV.", 
                "measure": "hSBA GMTs directed against N. meningitidis serogroup B.", 
                "safety_issue": "No", 
                "time_frame": "At day 1"
            }, 
            {
                "description": "To evaluate the antibody persistence 24 to 36 months after the completion of the vaccination course, in subjects who participated in the V72_28 study in Groups I to IV.", 
                "measure": "GMCs (ELISA) for vaccine antigen 287-953.", 
                "safety_issue": "No", 
                "time_frame": "At day 1"
            }, 
            {
                "description": "Groups A to F: from 1 month to 24 - 36 months after the completion of the vaccination course in the parent study (Group A and B: Visit 6, Groups C, D, E and F: Visit 5).\nGroup G to J: from 1 month to 24 - 36 months after the completion of the vaccination course in the parent study (Visit 3).", 
                "measure": "hSBA GMRs directed against N. meningitidis serogroup B", 
                "safety_issue": "No", 
                "time_frame": "At day 1"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01894919"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To evaluate the immune response at one month after a booster dose administered 24 to 36 months after completion of the vaccination course in the parent study (Groups A, C, E, G and I).", 
                "measure": "Percentage of subjects with hSBA titers \u22655 and \u22658 directed against strains of N. meningitidis serogroup B at Visit 1 (prevaccination) and Visit 2 (one month after the booster administration).", 
                "safety_issue": "No", 
                "time_frame": "30 (-4+10) days after study entry"
            }, 
            {
                "description": "To evaluate the immune response at one month after a booster dose administered 24 to 36 months after completion of the vaccination course in the parent study (Groups A, C, E, G and I).", 
                "measure": "Percentage of subjects with four-fold rise in titers from Visit 1 to Visit 2 directed against strains of N. meningitidis serogroup B.", 
                "safety_issue": "No", 
                "time_frame": "30 (-4+10) days after study entry"
            }, 
            {
                "description": "To evaluate the immune response at one month after a booster dose administered 24 to 36 months after completion of the vaccination course in the parent study (Groups A, C, E, G and I).", 
                "measure": "GMCs (ELISA) for vaccine antigen 287-953 at Visit 1 and Visit 2.", 
                "safety_issue": "No", 
                "time_frame": "30 (-4+10) days after study entry"
            }, 
            {
                "description": "To evaluate the immune response at one month after a booster dose administered 24 to 36 months after completion of the vaccination course in the parent study (Groups A, C, E, G and I).", 
                "measure": "Percentage of subjects with four-fold rise in concentrations of antigen 287-953 at Visit 1 and Visit 2", 
                "safety_issue": "No", 
                "time_frame": "30 (-4+10) days after study entry"
            }, 
            {
                "description": "To evaluate the immune response at one month after a booster dose administered 24 to 36 months after completion of the vaccination course in the parent study (Groups A, C, E, G and I).", 
                "measure": "hSBA GMTs directed against N. meningitidis serogroup B at Visit 1 and Visit 2.", 
                "safety_issue": "No", 
                "time_frame": "30 (-4+10) days after study entry"
            }, 
            {
                "description": "To evaluate the immune response at one month after a booster dose administered 24 to 36 months after completion of the vaccination course in the parent study (Groups A, C, E, G and I)", 
                "measure": "hSBA GMRs directed against N. meningitidis serogroup B: Visit 1 to Visit 2", 
                "safety_issue": "No", 
                "time_frame": "30 (-4+10) days after study entry"
            }, 
            {
                "description": "To evaluate the immune response of two catch-up doses of rMenB+OMV NZ administered 1 month apart to na\u00efve children (Group K, L and M).", 
                "measure": "Percentage of subjects with hSBA titers \u2265 1:5 and \u2265 1:8 directed against strains of N. meningitidis serogroup B at Visits 1, 2 and 3.", 
                "safety_issue": "No", 
                "time_frame": "60 (-4+10) days after study entry"
            }, 
            {
                "description": "To evaluate the immune response of two catch-up doses of rMenB+OMV NZ administered 1 month apart to na\u00efve children (Group K, L and M).", 
                "measure": "Percentage of subjects with four-fold rise in titers from Visit 1 to Visit 3 directed against strains of N. meningitidis serogroup B.", 
                "safety_issue": "No", 
                "time_frame": "60 (-4+10) days after study entry"
            }, 
            {
                "description": "To evaluate the immune response of two catch-up doses of rMenB+OMV NZ administered 1 month apart to na\u00efve children (Group K, L and M).", 
                "measure": "hSBA GMTs directed against N. meningitidis serogroup B at Visits 1, 2 and 3.", 
                "safety_issue": "No", 
                "time_frame": "60 (-4+10) days after study entry"
            }, 
            {
                "description": "To evaluate the immune response of two catch-up doses of rMenB+OMV NZ administered 1 month apart to na\u00efve children (Group K, L and M).", 
                "measure": "hSBA GMRs directed against N. meningitidis serogroup B: Visit 1 to Visit 3.", 
                "safety_issue": "No", 
                "time_frame": "60 (-4+10) days after study entry"
            }, 
            {
                "description": "To evaluate the immune response of two catch-up doses of rMenB+OMV NZ administered 1 month apart to na\u00efve children (Group K, L and M).", 
                "measure": "GMCs (ELISA) for vaccine antigen 287-953 at Visits 1, 2 and 3.", 
                "safety_issue": "No", 
                "time_frame": "60 (-4+10) days after study entry"
            }, 
            {
                "description": "To evaluate the immune response of two catch-up doses of rMenB+OMV NZ administered 1 month apart to na\u00efve children (Group K, L and M).", 
                "measure": "Percentage of subjects with four-fold rise in concentrations of antigen 287-953 at Visit 2 (one month after the first vaccination) as compared to pre-vaccination (Visit 1) and Visit 3 (one month after the second vaccination)", 
                "safety_issue": "No", 
                "time_frame": "60 (-4+10) days after study entry"
            }, 
            {
                "measure": "Safety will be assessed in terms of the number/percentage of subjects reporting adverse events, and number/percentage of reported adverse events for all subjects", 
                "safety_issue": "Yes", 
                "time_frame": "along all the trial"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Vaccines", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}